Next Article in Journal
Gentamicin Blocks the ACh-Induced BK Current in Guinea Pig Type II Vestibular Hair Cells by Competing with Ca2+ at the l-Type Calcium Channel
Previous Article in Journal
Supercritical Carbon Dioxide Extraction of Carotenoids from Pumpkin (Cucurbita spp.): A Review
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Design, Synthesis and Bioactivity of N-Glycosyl-N'-(5-substituted phenyl-2-furoyl) Hydrazide Derivatives

1
Guangdong Province Key Laboratory of Microbial Signals and Disease Control, Department of Plant Pathology, College of Natural Resources and Environment, South China Agricultural University, Guangzhou 510642, China
2
Division of Nanobiology, Advanced Integrated Science, Chiba University, Matsudo, Chiba 271-0092, Japan
3
Department of Applied Chemistry, College of Science, China Agricultural University, Beijing 100193, China
4
State Key Laboratory for Biology of Plant Diseases and Insect Pests, Institute of Plant Protection, Chinese Academy of Agricultural Sciences, Beijing 100193, China
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2014, 15(4), 6741-6756; https://doi.org/10.3390/ijms15046741
Submission received: 6 March 2014 / Revised: 30 March 2014 / Accepted: 10 April 2014 / Published: 21 April 2014
(This article belongs to the Section Biochemistry)

Abstract

:
Condensation products of 5-substituted phenyl-2-furoyl hydrazide with different monosaccharides d-glucose, d-galactose,d-mannose, d-fucose and d-arabinose were prepared. The anomerization and cyclic-acyclic isomers were investigated by 1H NMR spectroscopy. The results showed that, except for the d-glucose derivatives, which were in the presence of β-anomeric forms, all derivatives were in an acyclic Schiff base form. Their antifungal and antitumor activities were studied. The bioassay results indicated that some title compounds showed superior effects over the commercial positive controls.

Graphical Abstract

1. Introduction

Carbohydrates participate in various vital processes, showing important physiological and biological activities. In a recent review, Becker and coworkers [1] emphasized that the introduction of pharmacophores into sugar templates that possess dense stereochemical information is an excellent strategy for the development of bioactive compounds with rich structural diversity. Free reducing sugars (hemiacetal), which are often available from natural sources, react with α-heteroatom nucleophile hydrazide to give cyclic pyranoside adducts in predominantly β-anomeric form or the open chain hydrazone tautomer [25]. In fact, this intrinsic chemoselective condensation reactivity of carbohydrates has been skillfully employed in numerous applications, including biotin labeling [68], formation of glycoarrays [911], glycan capture for structural and functional glycomics [1214], and the generation of glycopeptide analogues [15,16].
Hydrazones containing an azometine (Schiff base) –NHN=CH– group possess various bioactivities such as antimicrobial, anticonvulsant, analgesic, antiinflammatory, antiplatelet, antitubercular and antitumoral activities [17]. A very famous example is the isonicotinic acid hydrazide (isoniazid) which showed very high inhibitory activity towards Mycobacterium tuberculosis H37Rv in vivo. Researchers synthesized isoniazid-hydrazones derivatives that were reported to have inhibitory activity in mice infected with various strains of M. tuberculosis and also showed less toxicity in these mice than isoniazid [18] because of the blockage of –NH2 group. These findings further support the growing importance of the synthesis of hydrazide-hydrazones compounds [19].
In our previous work, based on the hydrazide moiety, some diacylhydrazines (B, Scheme 1) [2024], semicarbazides (C, Scheme 1) [25], and acylhydrazones (D, Scheme 1) [26,27] derivatives containing 5-phenyl-2-furan were designed and synthesized. All the compounds showed diverse and significant bioactivities such as fungicidal, insecticidal, and antitumor activities. In continuation of our research on the synthesis of biological heterocyclic compounds, a series of novel glycosyl hydrazide derivatives containing 5-phenyl-2-furan moiety were designed and synthesized (Scheme 1). The ring-chain isomers were investigated by 1H NMR spectroscopy. Their antifungal and antitumor activities were evaluated.

2. Results and Discussion

2.1. Synthesis and Structure Elucidation

Glycosylhydrazides were obtained by condensation of equimolar amounts of the corresponding 5-substituted phenyl-2-furoyl hydrazide with the monosaccharides d-glucose, d-galactose, d-mannose, d-fucose, and d-arabinose in ethanol (Scheme 2).
The structures of all the compounds were characterized by 1H Nuclear Magnetic Resonance (NMR), Infrared Spectroscopy (IR) and High Resolution Mass Spectrometer (HRMS). In the IR spectra, the compounds showed absorption bands around 3200 to 3400 cm−1 originating from the O–H and N–H stretching vibration. The strong bands around 1640 to 1680 cm−1 were carbonyl vibration of the secondary amide. The bands between 1600 and 1620 cm−1 could be assigned to the C=N stretching vibration. Absorption bands around 1610, 1550 and 1475 cm−1 were attributed to the frame vibration of the phenyl and furan ring. Absorption bands around 1430, 1330 and 1260 cm−1 were attributed to the coupled modes of C–C and C–O stretching vibrations of the sugar residues [28,29]. The absorption bands around the 1150 and 1085 cm−1 region are characteristic for the pyranose form of hydrazines, and those around the 1075 cm−1 region for the acyclic form of hydrazones [2].
In the 1H NMR spectra, the ring-chain tautomers of the monosaccharides were obviously determined by the chemical shift of the proton in secondary amide CO–NH and the proton in imine N=CH in DMSO-d6 solution (Table 1).
If the isomer was a cyclic form, the signal of the amide CO–NH was appeared around 10.20 ppm and there was no imine N=CH signal, meanwhile the other N–NH signal was appeared around 5.87 ppm (Figure 1c). If the isomer was an acyclic form, the signal of the amide CO–NH was down-fileded to 11.50 ppm and the imine N=CH signal was appeared around 7.75 ppm (Figure 1e). The result showed that except the d-Glc, other monosaccharides such as d-Gal, d-Man, d-Fuc and d-Ara hydrazide derivatives were mainly the acyclic tautomers (Figure 1). The chemical shift of the anomeric H-1 in glucose 3.89 ppm and the coupling constant of 8.25 Hz indicated that the glucose was in the presence of β isomer.
The ring-chain interconversion of sugar hydrazones in solution usually depended on factors such as the sugar conformation, most probably on the proportion of aldehyde form in solution, the basicity of the hydrazine groups, and the solvent effect of proton-acceptor ability. About the solvent effect on ring-chain interconversion, there were evidence that sugar hydrazones were favorable to be acyclic form in dimethyl sulfoxide-d6 solution than others, such as pyridine-d5, methanol-d4 and deuterium oxide [2]. High pH values also stimulated the ring to chain conversion. The cyclic to acyclic conversion caused by increase in the basicity of hydrazine and the proton-acceptor ability of solvent might be interpreted according to the electronic theory. The strongly basic nitrogen atom of hydrazine group was in high electron-density. The electron could move easily from nitrogen to anomeric carbon of the sugars to form a C=N bong with sp2 hybridized orbital. The solvent with strong proton-acceptor ability could increase the basicity of the hydrazine group owing to the proton bonding with N–H group. In our study, the same solution and hydrazine were used (Figure 1), suggesting that the ring-chain tautomer was mainly caused due to the different monosaccharides. Some research [2] showed that glucose was prone to be cyclic form especially in dimethylsulfoxide (DMSO) solution. In this study, only glucose derivatives gave the cyclic form, which was consistent with the reported result [2]. Although the tautomerism was analyzed by 1H NMR, these were only the states in DMSO solution and did not reflect in any other solutions or in physiological environment. The equilibrium could move in other solutions, especially under the physiological situation.

2.2. Bioassay

2.2.1. Fungicidal Activity

The fungicidal activity and fungicidal spectra were evaluated by preliminary bioassay against 19 kinds of fungi (Table 2).
The result showed that the title compounds had broad fungicidal spectra, and most of them possessed good activity against the tested fungi at 50 μg·mL−1. Compound III-5 (Arabinose derivative) showed good activity against Phytophthora infestans and moderate activity against Phomopsis aspamgi and Cladosporium fulvum. Compound III-4 (Fucose derivative) showed moderate activity against P. aspamgi. Compound III-3 (Mannose derivative) showed good activity against P. infestans and Alternaria alternata. All the compounds had no activity against the Sclerotinia sclerotiorum except compound III-2 (Galactose derivative), which also showed excellent activity against the P. infestans, and moderate activity against A. alternate and P. aspamgi. For the glucose derivatives, fluorinated compounds such as III-6 (2,4-di-F), III-7 (4-F), and III-12 (3-F) showed better activity than the others. Among them, compound III-6 exhibited excellent activity against P. infestans and compound III-7 showed excellent activity against P. aspamgi. Both compounds III-6 and III-12 showed a significant inhibition effect on Valsa mali and C. fulvum. Compound III-12 also showed good activity against A. alternate and P. aspamgi. Compounds III-1 and III-9 showed considerable activity against Phytophthora melonis. Compound III-11 showed some inhibitory effect on the P. melonis. All the compounds showed poor activities against Fusarium graminearum, Pyricularia oryzae, Monilinia ariae, Gloeosporium musarum, Fusarium oxysporum f. sp. Niveum, Botrytis cinerea Pers., Colletotrichum orbiculare, Alternaria dauci and Colletotrichum phomoides.
EC50 and EC80 values against some fungi were studied and showed in Table 3. The EC50 values of III-2, III-5, III-8 against P. infestans were 4.493, 5.476, and 5.695 μg·mL−1, respectively, which were better than that of the positive control carbendazim (EC50 = 5.943 μg·mL−1). Among them, especially the compound III-8, which EC80 value of 195.839 μg·mL−1 was also better than that of the positive carbendazim (EC80 = 219.690 μg·mL−1). The EC50 and EC80 values of III-11 against Alternaria tenuis Nees were 6.181 and 431.342 μg·mL−1, respectively, which were better than that of the positive control thiram (EC50 = 8.831 μg·mL−1 and EC80 = 608.260 μg·mL−1). The EC50 of III-7 against Colletotrichum gloeosporioides was 4.962 μg·mL−1, which was close to that of the positive control carbendazim (EC50 = 4.613 μg·mL−1), while its EC80 value of 210.254 μg·mL−1 was better than that of the positive control (EC80 = 352.820 μg·mL−1). Also for this compound, its EC50 against P. aspamgi was 2.737 μg·mL−1, which was better than that of hymexazol (EC50 = 3.656 μg·mL−1), while their EC80 was the same with each other. The EC50 values of III-1 and III-9 against P. melonis were 5.179 and 7.586 μg·mL−1. The activity of compound III-1 was close to that of the positive control mancozeb (EC50 = 5.408 μg·mL−1) and better than compound III-9. Although their EC80 values of 840.493 and 500.113 μg·mL−1 were far away from that of the positive control mancozeb (EC80 = 211.870 μg·mL−1), meanwhile the EC80 value of compound III-9 was much better than compound III-1.

2.2.2. Antitumor Activity

Antitumor activity of title compounds was checked. The antitumor activity in Table 4 showed that some title compounds had great activity against human promyelocytic leukemic cells (HL-60). In which, the activity of compounds III-3, III-4 and III-5 (IC50 = 6.9, 1.2, and 19.4 μM) was better than that of the positive control doxorubicin (IC50 = 28.4 μM). Some compounds exhibited good activity against human gastric carcinoma cells (BGC-823), such as III-4, III-5, and III-6 (IC50 = 6.9, 1.2, and 19.4 μM), but which were lower than that of the doxorubicin (IC50 = 8.5 μM). Against human nasopharyngeal carcinoma cells (KB), only compound III-3 showed better activity (IC50 = 9.0 μM) than the positive control doxorubicin (IC50 = 28.4 μM). All the compounds showed poor activity against human hepatocellular carcinoma cells (Bel-7402).
The preliminary structure-activity relationship analysis indicated that compounds containing Man (III-3), Fuc (III-4), and Ara (III-5) showed better activity against human promyelocytic leukemic cells (HL-60). Although the compounds containing glucose showed poorer activity against HL-60 than doxorubicin, some of them also possessed considerable activity, and the substituted group had obvious effects on the activity. The compounds with fluoride and nitro group on the ortho (III-6 and III-9) or para-position (III-7 and III-8) showed better activity than the others. It could be deduced that the skeleton of 5-phenyl-2-furoyl hydrazide (hydrazone) displayed important antitumor activity, which was in agreement with our former results [2024,26,27].

3. Experimental Section

3.1. General Information

All the melting points were determined with a Cole-Parmer melting point apparatus while the thermometer was uncorrected. IR spectra were recorded on a NEXUS-470 FTIR (Nicolet) spectrometer with KBr pellets. 1H NMR spectra were recorded with Bruker DPX300 (Bruker, Billerica, MA, USA) and JEOL JNM-ECA500 instrument (JEOL Ltd., Tokyo, Japan), while tetramethylsilane was used as the internal standards. HRMS was performed with Bruker APEX IV instrument (Bruker, Billerica, MA, USA). Analytical thin-layer chromatography (TLC) was carried out on precoated plates (silica gel 60 F254). The developing solvents were chloroform and methanol (v/v: 6/1), and spots were visualized with ultraviolet (UV) light.

3.2. Synthetic Procedures

3.2.1. General Synthetic Procedure for the Key Intermediates

Intermediates II were synthesized from substituted aniline by Meerwein arylation reaction using the reported procedure [2027].

3.2.2. General Synthetic Procedure for the Title Compounds III

A mixture of monosaccaride I (0.05 mol) and 5-substituted phenyl-2-furoyl hydrazide II (0.05 mol) reacted in ethanol under reflux for 6–8 h. The reaction was catalyzed by drops of acetic acid. After cooling, the solvent was removed under reduced pressure, and the solid was recrystallized from ethanol to obtain the target compounds III.
All the synthesized compounds were solid. Their structures were confirmed by 1H NMR, IR, and ESI-HRMS.
N-(β-d-Glucopyranosyl)-N′-5-(4-chlorophenyl)-2-furoyl hydrazine (III-1). Yield 86%, m.p. 174–175 °C. Rf = 0.22. IR (KBr) νmax: 3254.29 (hydrazine, N–H), 2874.93 (aromatic, C=C–H), 1635.34 (hydrazide, C=O), 1475.28, 1364.39, 1321.00 (aromatic, C=C), 1278.57, 1221.68 (aromatic, C–C and C–O), 1195.65, 1164.79, 1090.55, 1028.84 cm−1. 1H NMR (500 MHz, DMSO-d6) δ: 3.01 (t, 1H, J = 9.5 Hz, H-4), 3.05 (t, 1H, J = 8.5 Hz, H-2), 3.14–3.24 (m, 2H, H-3, H-5), 3.48 (dd, 1H, J = 11.5, 5.5 Hz, H-6a), 3.72 (dd, 1H, J = 11.5, 2.5 Hz, H-6b), 3.89 (d, 1H, J = 8.5 Hz, H-1), 7.17 (d, 1H, J = 3.5 Hz, FuH), 7.28 (d, 1H, J = 3.5 Hz, FuH), 7.54 (d, 1H, J = 9.0 Hz, PhH), 7.67 (d, 1H, J = 8.5 Hz, PhH), 7.90 (d, 1H, J = 8.5 Hz, PhH), 7.97 (d, 1H, J = 8.5 Hz, PhH). ESI-HRMS calcd. for C17H19ClN2O7: [M + H]+ 399.0959; Found: 399.0965.
Aldehydo-d-Galactose-5-(4-chlorophenyl)-2-furoyl hydrazone (III-2). Yield 81%, m.p. 204–205 °C. Rf = 0.23. IR (KBr) νmax: 3486.75, 3208.00 (hydrazone, N–H), 2848.79 (aromatic, C=C–H), 1664.27 (hydrazide, C=O), 1625.15 (hydrazone, C=N), 1554.34, 1475.28 (aromatic, C=C), 1375.96, 1302.68, 1222.65 (aromatic, C–C and C–O), 1182.15, 1083.80, 1053.91 cm−1. 1H NMR (500 MHz, DMSO-d6) δ : 3.35–3.40 (m, 2H, H-4, H-6b), 3.50–3.54 (m, 2H, H-3, H-6a), 3.70 (q, 1H, J = 6.5 Hz, H-5), 4.16 (d, 1H, J = 6.5 Hz, H-2), 7.16 (d, 1H, J = 3.5 Hz, FuH), 7.31 (d, 1H, J = 3.5 Hz, FuH), 7.52 (d, 2H, J = 9.0 Hz, PhH), 7.65 (d, 1H, J = 8.5 Hz, PhH), 7.85 (d, 1H, J = 6.0 Hz, CH=N), 7.93 (d, 1H, J = 8.0 Hz, PhH). ESI-HRMS Calcd. for C17H19ClN2O7: [M + H]+ 399.0959; Found: 399.0946.
Aldehydo-d-Mannose-5-(4-chlorophenyl)-2-furoyl hydrazone (III-3). Yield 78%, m.p. 192–193 °C. Rf = 0.19. IR (KBr) νmax: 3268.75 (hydrazone, N–H), 2938.67 (aromatic, C=C–H), 1677.77 (hydrazide, C=O), 1619.47 (hydrazone, C=N), 1551.45, 1473.35, 1409.71 (aromatic, C=C), 1298.82, 1275.68, 1222.65 (aromatic, C–C and C–O), 1173.47, 1075.12, 1028.84 cm−1. 1H NMR (500 MHz, DMSO-d6) δ: 3.36–3.40 (m, 1H, H-5), 3.43–3.48 (m, 1H, H-6a), 3.54 (t, 1H, J = 8.0 Hz, H-4), 3.59–3.62 (m, 1H, H-6b), 3.69 (t, 1H, J = 8.0 Hz, H-3), 4.05–4.09 (m, 1H, H-2), 7.17 (d, 1H, J = 3.5 Hz, FuH), 7.30 (d, 1H, J = 3.5 Hz, FuH), 7.52 (d, 1H, J = 8.5 Hz, PhH), 7.66 (d, 1H, J = 8.5 Hz, PhH), 7.75 (d, 1H, J = 6.5 Hz, CH=N), 7.86 (d, 1H, J = 8.0 Hz, PhH), 7.93 (d, 1H, J = 8.0 Hz, PhH). ESI-HRMS Calcd. for C17H19ClN2O7: [M + H]+ 399.0959; Found: 399.0968.
Aldehydo-d-Fucose-5-(4-chlorophenyl)-2-furoyl hydrazone (III-4). Yield 74%, m.p. 212–213 °C. Rf = 0.18. IR (KBr) νmax: 3485.69, 3225.36 (hydrazone, N–H), 2897.43 (aromatic, C=C–H), 1663.30 (hydrazide, C=O), 1620.21 (hydrazone, C=N), 1552.42, 1475.28 (aromatic, C=C), 1376.93, 1300.75, 1221.68 (aromatic, C–C and C–O), 1180.22, 1025.94 cm–1. 1H NMR (500 MHz, DMSO-d6) δ: 1.07 (d, 1H, J = 6.5 Hz, CH3), 3.26 (t, 1H, J = 8.0 Hz, H-4), 3.49 (t, 1H, J = 8.5 Hz, H-5), 3.86–3.89 (m, 1H, H-3), 4.34–4.36 (m, 1H, H-2), 7.17 (d, 1H, J = 3.5 Hz, FuH), 7.31 (d, 1H, J = 3.5 Hz, FuH), 7.52 (d, 2H, J = 8.5 Hz, PhH), 7.65 (d, 1H, J = 9.0 Hz, PhH), 7.84 (d, 1H, J = 6.5 Hz, CH=N), 7.93 (d, 1H, J = 8.0 Hz, PhH). ESI-HRMS Calcd. for C17H19ClN2O6: [M + H]+ 383.1010; Found: 383.1023.
Aldehydo-d-Arabinose-5-(4-chlorophenyl)-2-furoyl hydrazone (III-5). Yield 72%, m.p. 212–213 °C. Rf = 0.20. IR (KBr) νmax: 3442.31, 3076.18 (hydrazone, N–H), 2845.34 (aromatic, C=C–H), 1666.47 (hydrazide, C=O), 1627.63 (hydrazone, C=N), 1546.63, 1473.35 (aromatic, C=C), 1322.93, 1272.79 (aromatic, C–C and C–O), 1169.62, 1061.62, 1036.55 cm–1. 1H NMR (500 MHz, DMSO-d6) δ: 3.36–3.43 (m, 2H, H-3, H-5a), 3.49–3.54 (m, 1H, H-5b), 3.56–3.60 (m, 1H, H-4), 4.31–4.33 (m, 1H, H-2), 7.16 (d, 1H, J = 3.5 Hz, FuH), 7.30 (d, 1H, J = 3.5 Hz, FuH), 7.52 (d, 1H, J = 9.0 Hz, PhH), 7.65 (d, 1H, J = 8.5 Hz, PhH), 7.83 (d, 1H, J = 6.0 Hz, CH=N), 7.86 (d, 1H, J = 8.5 Hz, PhH), 7.93 (d, 1H, J = 8.5 Hz, PhH). ESI-HRMS Calcd. for C16H17ClN2O6: [M + H]+ 369.0853; Found: 369.0842.
N-(β-d-Glucopyranosyl)-N′-5-(2,4-difluorophenyl)-2-furoyl hydrazine (III-6). Yield 75%, m.p. 184–185 °C. Rf = 0.23. IR (KBr) νmax: 3284.18 (hydrazine, N–H), 2931.26 (aromatic, C=C–H), 1655.59 (hydrazide, C=O), 1578.45, 1483.96 (aromatic, C=C), 1313.29, 1272.79 (aromatic, C–C and C–O), 1029.80 cm–1. 1H NMR (300 MHz, DMSO-d6) δ: 3.06–3.09 (m, 2H, H-2, H-4), 3.14–3.24 (m, 2H, H-3, H-5), 3.49 (dd, 1H, J = 11.7, 5.1 Hz, H-6a), 3.83 (dd, 1H, J = 12.0, 2.4 Hz, H-6b), 3.93 (d, 1H, J = 8.1 Hz, H-1), 6.96 (t, 1H, J = 3.6 Hz, FuH), 7.20–7.32 (m, 2H, FuH + PhH), 7.44–7.47 (m, 1H, PhH), 8.18–8.21 (m, 1H, PhH). ESI-HRMS Calcd. for C17H18F2N2O7: [M + H]+ 401.1160; Found: 401.1176.
N-(β-d-Glucopyranosyl)-N′-5-(4-fluorophenyl)-2-furoyl hydrazine (III-7). Yield 84%, m.p. 200–201 °C. Rf = 0.22. IR (KBr) νmax: 3447.13 (hydrazine, N–H), 2933.20 (aromatic, C=C–H), 1635.34 (hydrazide, C=O), 1560.13, 1489.74 (aromatic, C=C), 1314.25, 1224.58 (aromatic, C–C and C–O), 1158.04, 1025.94 cm–1. 1H NMR (300 MHz, DMSO-d6) δ: 3.06–3.10 (m, 2H, H-2, H-4), 3.14–3.24 (m, 2H, H-3, H-5), 3.48 (dd, 1H, J = 12.3, 5.6 Hz, H-6a), 3.81 (dd, 1H, J = 12.2, 2.7 Hz, H-6b), 3.92 (d, 1H, J = 8.7 Hz, H-1), 7.14 (d, J = 3.6 Hz, 1H, FuH), 7.33 (d, J = 3.6 Hz, 1H, FuH), 7.37 (d, J = 9.0 Hz, 2H, PhH), 7.99–8.02 (m, 2H, PhH). ESI-HRMS Calcd. for C17H19FN2O7: [M + H]+ 383.1255; Found: 383.1267.
N-(β-d-Glucopyranosyl)-N′-5-(4-nitrophenyl)-2-furoyl hydrazine (III-8). Yield 72%, m.p. 124–125 °C. Rf = 0.21. IR (KBr) νmax: 3344.93 (hydrazine, N–H), 2968.74 (aromatic, C=C–H), 1614.13 (hydrazide, C=O), 1486.85 (aromatic, C=C), 1332.57 (aromatic, C–C and C–O), 1078.01, 1021.12 cm−1. 1H NMR (300 MHz, DMSO-d6) δ: 3.06 (t, 1H, J = 9.6 Hz, H-4), 3.08 (t, 1H, J = 8.1 Hz, H-2), 3.18–3.24 (m, 2H, H-3, H-5), 3.49 (m, 1H, H-6a), 3.74 (m, 1H, H-6b), 3.91 (d, 1H, J = 8.5 Hz, H-1), 7.36 (d, 1H, J = 3.6 Hz, FuH), 7.58–7.63 (m, 3H, FuH + 2PhH), 8.30 (d, 2H, J = 9.0 Hz, PhH). ESI-HRMS Calcd. for C17H19N3O9: [M + H]+ 410.1200; Found: 410.1189.
N-(β-d-Glucopyranosyl)-N′-5-(2-nitrophenyl)-2-furoyl hydrazine (III-9). Yield 69%, m.p. 133–134 °C. Rf = 0.23. IR (KBr) νmax: 3290.93 (hydrazine, N–H), 2897.86 (aromatic, C=C–H), 1646.91 (hydrazide, C=O), 1586.77, 1519.63, 1472.38 (aromatic, C=C), 1356.68, 1316.18, 1251.57 (aromatic, C–C and C–O), 1077.05 cm−1. 1H NMR (300 MHz, DMSO-d6) δ: 3.04–3.10 (m, 2H, H-2, H-4), 3.12–3.21 (m, 2H, H-3, H-5), 3.46 (m, 1H, H-6a), 3.80 (m, 1H, H-6b), 3.95 (d, 1H, J = 8.5 Hz, H-1), 6.90 (d, J = 3.5 Hz,1H, FuH), 7.34 (d, J = 3.5 Hz, 1H, FuH), 7.65–7.69 (m, 2H, PhH), 7.78–7.82 (m, 1H, PhH), 7.97–8.01 (m, 1H, PhH). ESI-HRMS Calcd. for C17H19N3O9: [M + H]+ 410.1200; Found: 410.1219.
N-(β-d-Glucopyranosyl)-N′-5-(2-chlorophenyl)-2-furoyl hydrazine (III-10). Yield 81%, m.p. 160–161 °C. Rf = 0.21. IR (KBr) νmax: 3320.82 (hydrazine, N–H), 2925.48 (aromatic, C=C–H), 1654.62 (hydrazide, C=O), 1560.13, 1472.38 (aromatic, C=C), 1315.21(aromatic, C–C and C–O), 1073.19 cm–1. 1H NMR (300 MHz, DMSO-d6) δ: 3.01 (t, 1H, J = 9.6 Hz, H-4), 3.06 (t, 1H, J = 8.7 Hz, H-2), 3.12–3.24 (m, 2H, H-3, H-5), 3.46 (dd, 1H, J = 12.6, 5.1 Hz, H-6a), 3.82 (dd, 1H, J = 12.6, 2.7 Hz, H-6b), 3.92 (d, 1H, J = 8.4 Hz, H-1), 7.31 (d, J = 3.6 Hz, 1H, FuH), 7.39 (d, J = 3.6 Hz, 1H, FuH), 7.43–7.54 (m, 2H, PhH), 7.60–7.63 (m, 1H, PhH), 8.18–8.22 (m, 1H, PhH). ESI-HRMS Calcd. for C17H19ClN2O7: [M + H]+ 399.0959; Found: 399.0968.
N-(β-d-Glucopyranosyl)-N′-5-(4-methylphenyl)-2-furoyl hydrazine (III-11). Yield 79%, m.p. 180–181 °C. Rf = 0.23. IR (KBr) νmax: 3456.78 (hydrazine, N–H), 2906.20 (aromatic, C=C–H), 1638.23 (hydrazide, C=O), 1577.49, 1491.67, 1454.06 (aromatic, C=C), 1313.29, 1271.82 (aromatic, C–C and C–O), 1078.01, 1018.23 cm–1. 1H NMR (300 MHz, DMSO-d6) δ: 2.34 (s,3H,CH3), 3.02 (t, 1H, J = 9.6 Hz, H-4), 3.06 (t, 1H, J = 8.1 Hz, H-2), 3.16–3.23 (m, 2H, H-3, H-5), 3.49 (dd, 1H, J = 12.3, 5.1 Hz, H-6a), 3.69 (dd, 1H, J = 12.2, 2.7 Hz, H-6b), 3.95 (d, 1H, J = 8.8 Hz, H-1), 7.02 (d, 1H, J = 3.6 Hz, FuH), 7.27–7.33 (m, 3H, FuH +2PhH), 7.78–7.83 (m, 2H, PhH). ESI-HRMS Calcd. for C18H22N2O7: [M + H]+ 379.1505; Found: 379.1516.
N-(β-d-Glucopyranosyl)-N′-5-(3-fluorophenyl)-2-furoyl hydrazine (III-12). Yield 78%, m.p. 184–185 °C. Rf = 0.22. IR (KBr) νmax: 3380.60 (hydrazine, N–H), 2879.62 (aromatic, C=C–H), 1660.41 (hydrazide, C=O), 1587.13, 1473.35, 1412.60 (aromatic, C=C), 1316.18 (aromatic, C–C and C–O), 1194.69, 1074.16, 1028.84 cm−1. 1H NMR (300 MHz, DMSO-d6) δ: 3.02–3.10 (m, 2H, H-2, H-4), 3.12–3.21 (m, 2H, H-3, H-5), 3.43 (dd, 1H, J = 12.3, 5.1 Hz, H-6a), 3.76 (dd, 1H, J = 12.6, 2.7 Hz, H-6b), 3.92 (d, 1H, J = 8.4 Hz, H-1), 7.26–7.31 (m, 2H, FuH + PhH), 7.45 (d, J = 3.6 Hz, 1H, FuH), 7.55–7.58 (m, 1H, PhH), 7.74–7.77 (m, 1H, PhH), 7.98–8.01 (m, 1H, PhH). ESI-HRMS Calcd. for C17H19FN2O7: [M + H]+ 383.1255; Found: 383.1264.

3.3. Bioassay

3.3.1. Fungicidal Activity

The fungicidal activity and antifungal spectra of title compounds were evaluated using the mycelium growth rate test at 50 μg·mL−1. The fungi were provided and maintained by Department of Applied Chemistry, College of Science, China Agricultural University, Beijing, China. The commercial fungicides mancozeb, carbendazim, thiram, and hymexazol were used as positive controls. EXCEL2007 was applied to analyze bioassay data. Analysis of difference significance was performed using SPSS v.18.0 (SPSS Inc., Chicago, IL, USA).
The fungicidal activity of title compounds was assessed using the radial growth test on potato dextrose agar (PDA). The compounds were dissolved in acetone and mixed with sterile molten PDA to obtain different concentrations of 50, 25, 12.5, 6.25, 3.13, 1.56 and 0.78 μg·mL−1. Three replicates were used per treatment. After an incubation period of 96 h at 23 °C under a regular 12:12 h light:dark regimen, mycelial growth diameters were measured and the inhibition percentages relative to the control with 1% acetone were calculated. The inhibition rate was calculated according to the following formula:
I 1 = ( D ¯ 1 - D ¯ 0 ) / D ¯ 1 × 100 %
where I1 is the inhibition rate, 1 is the average area of mycelia in the blank test, and 0 is the average area of mycelia in the presence of compounds. The EC50 and EC80 values were calculated using log-probit analysis, and the results were given in Table 1.

3.3.2. Antitumor Activity

All the title compounds were dissolved in DMSO and screened for preliminary anticancer activity against four different cell lines: a human promyelocytic leukemic cell line (HL-60), a human hepatocellular carcinoma cell line (Bel-7402), a human gastric carcinoma cell line (BGC-823), and a human nasopharyngeal carcinoma cell line (KB) at concentration gradient of 0.1, 1.0, 10, 50 and 100 μM. The commercial drug doxorubicin was used as positive control in the bioassay. Three replicates were performed.
The four types of cell line were grown and maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), penicillin (100 U·mL−1), and streptomycin (100 μg·mL−1) at 37 °C in humidified incubators in an atmosphere of 5% CO2.
All the experiments were performed on exponentially growing cancer cells. Numbers of viable cancer cells were determined by MTT ([3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazoliumbromide]) [30] and SRB (sulforhodamine B) [31] assays. The cancer cells (1 ~ 2.5 × 104 cells·mL−1) were inoculated in 96-well culture plates (180 μL/well). After 24 h, 20 μL of culture medium containing compounds of various concentrations were added to the wells and, the cells were incubated for 48 h. 20 μL of RPMI-1640 medium was added to the control cells. HL-60 cells were assayed by MTT, and the Bel-7402, BGC-823 and KB cells were assayed by SRB. The absorbance of each well was measured using a microculture plate reader at 570 nm (MTT) and 540 nm (SRB). The inhibition rate was calculated according to the following formula:
Inhibition rate = ( O D control - OD treated ) / OD control × 100 %

4. Conclusions

In summary, a novel series of N-glycosyl-N′-(5-substituted phenyl-2-furoyl) hydrazide derivatives were synthesized in good yields. The anomerization and ring-chain isomers were confirmed by 1H NMR spectroscopy. Their antifungal and antitumor tests indicated that some title compounds showed superiority over the commercial positive controls during the present studies. Comparing title compounds III with lead compounds B (diacylhydrazides), C (semicarbazides), and D (acylhydrazones) (Scheme 1), it can be seen that the modification with sugars in hydrazide molecules is important for improving the antifungal and antitumor activity. These compounds could be lead compounds for further development.

Acknowledgments

We express our gratitude to Jingrong Cui and Ruiqing Wang (State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Science, Peking University) for their kind help in bioassay of antitumor activity. We greatly acknowledge the financial supports for this work from the National Natural Science Foundation of China (21102173), the State Key Laboratory for Biology of Plant Diseases and Insect Pests (SKLOF201411), the President Science Foundation of South China Agricultural University (4200-K13014), the Japan Society for the Promotion of Science (JSPS, ID No. P10100), and Advanced Multi-Career Training Program for Postdoctoral Scholars from JST (200-1).

Conflicts of Interest

The authors declare no conflict of interest.
  • Author ContributionsConceived and designed the experiments: Zining Cui, Jiazhen Jiang and Yoshihiro Nishida. Performed the experiments: Zining Cui, Zining Cui and Jiazhen Jiang. Analyzed the data: Zining Cui, Jiazhen Jiang and Xinling Yang. Wrote the paper: Zining Cui and Jiazhen Jiang.

References

  1. Meutermans, W.; Le, G.T.; Becker, B. Carbohydrates as scaffolds in drug discovery. Chem. Med. Chem 2006, 1, 1164–1194. [Google Scholar]
  2. Takeda, Y. Determination of sugar hydrazide and hydrazone structures in solution. Carbohydr. Res 1979, 77, 9–23. [Google Scholar]
  3. Bendiak, B. Preparation, conformation, and mild hydrolysis of 1-glycosyl-2-acetylhydrazines of the hexoses, pentoses, 2-acetamido-2-deoxyhexoses, and fucose. Carbohydr. Res 1997, 304, 85–90. [Google Scholar]
  4. Peri, F.; Dumy, P.; Mutter, M. Chemo- and stereo-selective glycosylation of hydroxylamino derivatives: A versatile approach to glycoconjugates. Tetrahedron 1998, 54, 12269–12278. [Google Scholar]
  5. Gudmundsdottir, A.V.; Paul, C.E.; Nitz, M. Stability studies of hydrazide and hydroxylamine-based glycoconjugates in aqueous solution. Carbohydr. Res 2009, 344, 278–284. [Google Scholar]
  6. Mahal, L.K.; Yarema, K.J.; Bertozzi, C.R. Engineering chemical reactivity on cell surfaces through oligosaccharide biosynthesis. Science 1997, 276, 1125–1128. [Google Scholar]
  7. Leteux, C.; Childs, R.A.; Chai, W.; Stoll, M.S.; Kogelberg, H.; Feizi, T. Biotinyl-l-3-(2-naphthyl)-alanine hydrazide derivatives of N-glycans: Versatile soliD-phase probes for carbohydrate-recognition studies. Glycobiology 1998, 8, 227–236. [Google Scholar]
  8. Lee, J.H.; Baker, T.J.; Mahal, L.K.; Zabner, J.; Bertozzi, C.R.; Wiemer, D.F.; Welsh, M.J. Engineering novel cell surface receptors for virus-mediated gene transfer. J. Biol. Chem 1999, 274, 21878–21884. [Google Scholar]
  9. Lee, M.; Shin, I. Facile Preparation of carbohydrate microarrays by site-specific, covalent immobilization of unmodified carbohydrates on hydrazide-coated glass slides. Org. Lett 2005, 7, 4269–4272. [Google Scholar]
  10. Park, S.; Lee, M.-R.; Shin, I. Construction of carbohydrate microarrays by using one-step, direct immobilizations of diverse unmodified glycans on solid surfaces. Bioconjug. Chem 2009, 20, 155–162. [Google Scholar]
  11. Godula, K.; Bertozzi, C.R. Synthesis of glycopolymers for microarray applications via ligation of reducing sugars to a poly (acryloyl hydrazide) scaffold. J. Am. Chem. Soc 2010, 132, 9963–9965. [Google Scholar]
  12. Zhao, Y.; Kent, S.B.H.; Chait, B.T. Rapid, sensitive structure analysis of oligosaccharides. Proc. Natl. Acad. Sci. USA 1997, 94, 1629–1633. [Google Scholar]
  13. Furukawa, J.; Shinohara, Y.; Kuramoto, H.; Miura, Y.; Shimaoka, H.; Kurogochi, M.; Nakano, M.; Nishimura, S.-I. Comprehensive approach to structural and functional glycomics based on chemoselective glycoblotting and sequential tag conversion. Anal. Chem 2008, 80, 1094–1101. [Google Scholar]
  14. Bohorov, O.; Andersson-Sand, H.; Hoffmann, J.; Blixt, O. Arraying glycomics: A novel bi-functional spacer for one-step microscale derivatization of free reducing glycans. Glycobiology 2006, 16, 21C–27C. [Google Scholar]
  15. Rodriguez, E.C.; Marcaurelle, L.A.; Bertozzi, C.R. Aminooxy-, hydrazide-, and thiosemicarbazide-functionalized saccharides: Versatile reagents for glycoconjugate synthesis. J. Org. Chem 1998, 63, 7134–7135. [Google Scholar]
  16. Peluso, S.; Imperiali, B. Asparagine surrogates for the assembly of N-linked glycopeptide mimetics by chemoselective ligation. Tetrahedron Lett 2001, 42, 2085–2087. [Google Scholar]
  17. Rollas, S.; Küçükgüzel, Ş.G. Biological activities of hydrazone derivatives. Molecules 2007, 12, 1910–1939. [Google Scholar]
  18. Sah, P.P.T.; Peoples, S.A. Isonicotinoyl hydrazones as antitubercular agents and derivatives for identification of aldehydes and ketones. J. Am. Pharm. Assoc 1954, 43, 513–524. [Google Scholar]
  19. Yu, Y.; Kalinowski, D.S.; Kovacevic, Z.; Siafakas, A.R.; Jansson, P.J.; Stefani, C.; Lovejoy, D.B.; Sharpe, P.C.; Bernhardt, P.V.; Richardson, D.R. Thiosemicarbazones from the old to new: Iron chelators that are more than just ribonucleotide reductase inhibitors. J. Med. Chem 2009, 52, 5271–5294. [Google Scholar]
  20. Cui, Z.N.; Wang, Z.; Li, Y.; Zhou, X.Y.; Ling, Y.; Yang, X.L. Synthesis of 5-(chlorophenyl)-2-furancarboxylic acid 2-(benzoyl) hydrazide derivatives and determination of their insecticidal activity. Chin. J. Org. Chem 2007, 27, 1300–1304. [Google Scholar]
  21. Cui, Z.N.; Huang, J.; Li, Y.; Ling, Y.; Yang, X.L.; Chen, F.H. Synthesis and bioactivity of novel N,N′-diacylhydrazine derivatives containing furan (I). Chin. J. Chem 2008, 26, 916–922. [Google Scholar]
  22. Li, X.C.; Yang, X.L.; Cui, Z.N.; Li, Y.; He, H.W.; Ling, Y. Synthesis and bioactivity of novel N,N′-diacylhydrazine derivatives containing furan (II). Chin. J. Chem 2010, 28, 1233–1239. [Google Scholar]
  23. Cui, Z.N.; Zhang, L.; Huang, J.; Yang, X.L.; Ling, Y. Synthesis and bioactivity of novel N,N′-diacylhydrazine derivatives containing furan (III). Chin. J. Chem 2010, 28, 1257–1266. [Google Scholar]
  24. Cui, Z.N.; Shi, Y.X.; Zhang, L.; Ling, Y.; Li, B.J.; Nishida, Y.; Yang, X.L. Synthesis and fungicidal activity of novel 2,5-disubstituted-1,3,4-oxadiazole derivatives. J. Agric. Food Chem 2012, 60, 11649–11656. [Google Scholar]
  25. Cui, Z.N.; Ling, Y.; Li, B.J.; Li, Y.Q.; Rui, C.H.; Cui, J.R.; Shi, Y.X.; Yang, X.L. Synthesis and bioactivity of N-benzoyl-N′-[5-(2′-substituted phenyl)-2-furoyl] semicarbazide derivatives. Molecules 2010, 15, 4267–4282. [Google Scholar]
  26. Cui, Z.N.; Li, Y.; Huang, J.; Ling, Y.; Cui, J.R.; Wang, R.Q.; Yang, X.L. New class of potent antitumor acylhydrazone derivatives containing furan. Eur. J. Med. Chem 2010, 45, 5576–5584. [Google Scholar]
  27. Cui, Z.N.; Yang, X.L.; Shi, Y.X.; Uzawa, H.; Cui, J.R.; Dohi, H.; Nishida, Y. Molecular design, synthesis and bioactivity of glycosyl hydrazine and hydrazone derivatives: Notable effects of the sugar moiety. Bioorg. Med. Chem. Lett 2011, 21, 7193–7196. [Google Scholar]
  28. Cael, J.J.; Koenig, J.L.; Blackwell, J. Infrared and Raman spectroscopy of carbohydrates. IV. Identification of configuration-and conformation-sensitive modes for d-glucose by normal coordinate analysis. Carbohydr. Res 1974, 32, 79–91. [Google Scholar]
  29. Hineno, M. Infrared spectra and normal vibrations of β-d-glucopyranose. Carbohydr. Res 1977, 56, 219–227. [Google Scholar]
  30. Denizot, F.; Lang, R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods 1986, 89, 271–277. [Google Scholar]
  31. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst 1991, 83, 757–766. [Google Scholar]
Figure 1. 500 MHz 1H NMR spectra of condensation products of 5-(4′-chlorophenyl)-2-furoyl hydrazide with different monosaccharides: d-arabinose (a); d-fucose (b); d-glucose (c); d-galctose (d); and d-mannose (e) in DMSO-d6 solution.
Figure 1. 500 MHz 1H NMR spectra of condensation products of 5-(4′-chlorophenyl)-2-furoyl hydrazide with different monosaccharides: d-arabinose (a); d-fucose (b); d-glucose (c); d-galctose (d); and d-mannose (e) in DMSO-d6 solution.
Ijms 15 06741f1
Scheme 1. Designed strategy for title compounds.
Scheme 1. Designed strategy for title compounds.
Ijms 15 06741f2
Scheme 2. Condensation reactivity and equilibrium between cyclic and acyclic forms of the monosaccharide. III-1: Glc, R = 4-Cl; III-2: Gal, R = 4-Cl; III-3: Man, R = 4-Cl; III-4: Fuc, R = 4-Cl; III-5: Ara, R = 4-Cl; III-6: Glc, R = 2,4-di-F; III-7: Glc, R = 4-F; III-8: Glc, R = 4-NO2; III-9: Glc, R = 2-NO2; III-10: Glc, R = 2-Cl; III-11: Glc, R = 4-Me; III-12: Glc, R = 3-F.
Scheme 2. Condensation reactivity and equilibrium between cyclic and acyclic forms of the monosaccharide. III-1: Glc, R = 4-Cl; III-2: Gal, R = 4-Cl; III-3: Man, R = 4-Cl; III-4: Fuc, R = 4-Cl; III-5: Ara, R = 4-Cl; III-6: Glc, R = 2,4-di-F; III-7: Glc, R = 4-F; III-8: Glc, R = 4-NO2; III-9: Glc, R = 2-NO2; III-10: Glc, R = 2-Cl; III-11: Glc, R = 4-Me; III-12: Glc, R = 3-F.
Ijms 15 06741f3
Table 1. 1H NMR spectra data of the condensation products of 5-(4′-chlorophenyl)-2-furoyl hydrazide with different monosaccharides.
Table 1. 1H NMR spectra data of the condensation products of 5-(4′-chlorophenyl)-2-furoyl hydrazide with different monosaccharides.
CompoundsMonosaccharideChemical Shift (500 MHz, DMSO-d6)Tautomer

H-1NH-1NH-2
III-1Glc3.89 (t, 8.5 Hz)5.87 (t, 4.0 Hz)10.18 (s)β-pyronose
III-2Gal7.85 (d, 6.0 Hz)11.52 (s)acyclic
III-3Man7.75 (d, 6.5 Hz)11.54 (s)acyclic
III-4Fuc7.84 (d, 6.5 Hz)11.52 (s)acyclic
III-5Ara7.83 (d, 6.0 Hz)11.53 (s)acyclic
Table 2. The preliminary bioassay against 19 fungi at 50 μg·mL−1.
Table 2. The preliminary bioassay against 19 fungi at 50 μg·mL−1.
FungiInhibitory Rate (%) ± SEM

III-1III-2III-3III-4III-5III-6III-7III-8III-10III-11III-12III-13
Fusarium graminearum23.44 ± 4.2443.75 ± 4.96
Pyricularia oryzae30.24 ± 4.5926.39 ± 4.4164.41 ± 4.7935.82 ± 4.79
Phytophthora infestans90.16 ± 2.9873.24 ± 4.4326.48 ± 4.4177.48 ± 4.1887.80 ± 3.2741.67 ± 4.9363.90 ± 4.8038.20 ± 4.86
Alternaria alternata54.24 ± 4.9858.13 ± 4.9365.40 ± 4.7632.18 ± 4.6741.52 ± 4.9322.15 ± 4.1558.13 ± 4.93
Valsa mali41.64 ± 4.9345.82 ± 4.9846.94 ± 4.9946.20 ± 4.9979.13 ± 4.0640.86 ± 4.9245.07 ± 4.9836.08 ± 4.8053.73 ± 4.99
Colletotrichum gloeosporioides24.92 ± 4.3334.45 ± 4.7540.29 ± 4.9032.12 ± 4.6732.12 ± 4.6736.73 ± 4.82
Monilinia ariae39.31 ± 4.8833.75 ± 4.7321.90 ± 4.1435.63 ± 4.79
Gloeosporium musarum21.75 ± 4.1320.84 ± 4.0634.76 ± 4.7621.75 ± 4.1330.13 ± 4.5930.56 ± 4.61
Fusarium oxysporum f. sp. Niveum29.94 ± 4.5836.60 ± 4.8227.94 ± 4.4931.35 ± 4.6425.03 ± 4.3328.80 ± 4.5324.73 ± 4.31
Botrytis cinerea Pers.28.09 ± 4.4921.15 ± 4.08
Colletotrichum orbiculare42.45 ± 4.9425.68 ± 4.3738.73 ± 4.8755.25 ± 4.9721.46 ± 4.11
Phytophthora melonis58.03 ± 4.9432.12 ± 4.6731.03 ± 4.6329.27 ± 4.5532.55 ± 4.69
Sclerotinia sclerotiorum70.84 ± 4.5432.76 ± 4.69
Phomopsis aspamgi64.71 ± 4.7825.44 ± 4.3669.36 ± 4.6155.39 ± 4.9743.89 ± 4.9691.07 ± 2.8531.07 ± 4.6347.16 ± 4.9967.29 ± 4.6968.95 ± 4.63
Alternaria dauci20.09 ± 4.0128.01 ± 4.4937.92 ± 4.8528.01 ± 4.4922.77 ± 4.1922.77 ± 4.1922.77 ± 4.19
Fusarium graminearum55.56 ± 4.9724.54 ± 4.3026.28 ± 4.40
Cladosporium fulvum47.24 ± 4.9942.81 ± 4.9535.84 ± 4.8054.22 ± 4.9870.05 ± 4.5850.09 ± 5.0045.78 ± 4.9842.81 ± 4.9566.69 ± 4.71
Colletotrichum phomoides26.53 ± 4.4148.98 ± 5.0048.98 ± 5.0026.53 ± 4.4138.27 ± 4.86
Alternaria tenuis Nees21.84 ± 4.1331.76 ± 4.6624.39 ± 4.2943.21 ± 4.9531.76 ± 4.6624.39 ± 4.2941.00 ± 4.92
– means no activity.
Table 3. Fungicidal activity of title compounds.
Table 3. Fungicidal activity of title compounds.
FungiCompoundsRRegression EquationEC50 (95% Confidence Interval)/μg·mL−1EC80 (95% Confidence Interval)/μg·mL−1
P. infestansIII-20.987y = 2.283x – 10.6785.476 (4.857~6.132)456.337 (405.314~511.740)
III-50.988y = 2.294x – 10.7155.695 (5.107~6.335)485.901 (435.433~540.053)
III-60.999y = 1.950x – 9.104.493 (4.426~4.507)195.839 (193.750~197.278)
mancozeb0.969y = 1.923x – 8.9734.385 (3.329~5.776)182.460 (138.293~239.924)

A. tenuis NeesIII-110.979y = 2.191x – 10.1656.181 (5.111~7.437)431.342 (356.891~519.335)
thiram0.976y = 2.183x – 9.9698.831 (8.144~9.574)608.260 (559.935~658.234)

C. gloeosporioidesIII-70.991y = 1.932x – 8.9644.962 (4.580~5.384)210.254 (193.593~227.579)
carbendazm0.993y = 2.237x – 10.5214.613 (4.331~4.912)352.820 (330.646~375.017)

P. aspamgiIII-70.977y = 1.732x – 8.2222.737 (2.232~3.366)78.767 (64.0567~96.5630)
hymexazol0.985y = 2.018x – 9.5273.656 (2.232~3.366)78.770 (64.057~96.563)

P. melonisIII-10.985y = 2.427x – 11.2547.586 (6.647~8.696)840.493 (733.256~959.342)
III-90.996y = 2.354x – 11.0535.179 (5.027~5.403)500.113 (481.424~517.398)
mancozeb0.991y = 1.892x – 8.7275.408 (4.987~5.863)211.870 (195.086~229.334)
Table 4. Antitumor activity of the title compounds.
Table 4. Antitumor activity of the title compounds.
CompoundsIC50 (μM)

HL-60BGC-823Bel-7402KB
III-1267.9184.62.6 × 105586.2
III-2167.090.9133.4166.8
III-36.8151.9144.59.0
III-41.234.0169.931.9
III-519.447.2106.8118.9
III-631.743.5110.440.7
III-778.9193.3356.7489.2
III-861.996.1258.0116.6
III-938.7550.2178.3337.8
III-101523.492.8174.81.2 × 105
III-115797.3119.32.5 × 104100.7
III-12315.176.23.5 × 1061588.0
doxorubicin28.48.56.711.9

Share and Cite

MDPI and ACS Style

Cui, Z.; Su, H.; Jiang, J.; Yang, X.; Nishida, Y. Design, Synthesis and Bioactivity of N-Glycosyl-N'-(5-substituted phenyl-2-furoyl) Hydrazide Derivatives. Int. J. Mol. Sci. 2014, 15, 6741-6756. https://doi.org/10.3390/ijms15046741

AMA Style

Cui Z, Su H, Jiang J, Yang X, Nishida Y. Design, Synthesis and Bioactivity of N-Glycosyl-N'-(5-substituted phenyl-2-furoyl) Hydrazide Derivatives. International Journal of Molecular Sciences. 2014; 15(4):6741-6756. https://doi.org/10.3390/ijms15046741

Chicago/Turabian Style

Cui, Zining, Hang Su, Jiazhen Jiang, Xinling Yang, and Yoshihiro Nishida. 2014. "Design, Synthesis and Bioactivity of N-Glycosyl-N'-(5-substituted phenyl-2-furoyl) Hydrazide Derivatives" International Journal of Molecular Sciences 15, no. 4: 6741-6756. https://doi.org/10.3390/ijms15046741

APA Style

Cui, Z., Su, H., Jiang, J., Yang, X., & Nishida, Y. (2014). Design, Synthesis and Bioactivity of N-Glycosyl-N'-(5-substituted phenyl-2-furoyl) Hydrazide Derivatives. International Journal of Molecular Sciences, 15(4), 6741-6756. https://doi.org/10.3390/ijms15046741

Article Metrics

Back to TopTop